188 related articles for article (PubMed ID: 15953079)
1. Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
Alexandrescu DT; Koulova L; Wiernik PH
Clin Exp Dermatol; 2005 Jul; 30(4):391-4. PubMed ID: 15953079
[TBL] [Abstract][Full Text] [Related]
2. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
3. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
5. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
Prasad HK; Kaushal V; Mehta P
Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
[TBL] [Abstract][Full Text] [Related]
6. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
[TBL] [Abstract][Full Text] [Related]
7. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
8. Multiple bulky cutaneous plasmacytomas with CNS relapse without bone marrow involvement during the course of a lambda light chain myeloma.
Serefhanoglu S; Haznedaroglu IC; Goker H; Buyukasik Y; Ozcebe OI
Onkologie; 2009 Nov; 32(11):662-4. PubMed ID: 19887870
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
10. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell leukaemia mimicking acute monocytic leukaemia in the course of multiple myeloma.
Eclache V; Lusina D; Lejeune F; Casassus P; Smadja N; Lortholary P
Nouv Rev Fr Hematol (1978); 1993 Aug; 35(4):419-22. PubMed ID: 8414961
[TBL] [Abstract][Full Text] [Related]
12. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
14. [Contemporaneous presentation of plasma cell leukemia and multiple myeloma. Description of a clinical case with a biclonal component].
Pasqualetti P; Casale R; Colantonio D; Natali G
Minerva Med; 1987 Jul; 78(13):907-10. PubMed ID: 3601136
[TBL] [Abstract][Full Text] [Related]
15. Kappa light chain myeloma with initial cutaneous involvement.
Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
[No Abstract] [Full Text] [Related]
16. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
[TBL] [Abstract][Full Text] [Related]
17. Neutrophilic dermatosis complicating lenalidomide therapy.
Thieu KP; Rosenbach M; Xu X; Kist JM
J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
[TBL] [Abstract][Full Text] [Related]
18. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
[TBL] [Abstract][Full Text] [Related]
19. Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.
Ballanti S; Mastrodicasa E; Bolli N; Lotti F; Capolsini I; Berchicci L; Merigiola C; Giordano G; Tabilio A
Nat Clin Pract Oncol; 2007 Dec; 4(12):722-5. PubMed ID: 18037876
[TBL] [Abstract][Full Text] [Related]
20. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
